Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2021 - 2026)

Neuphoria Therapeutics (NEUP) has 6 years of Other Non-Current Liabilities data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 45.76% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (down 45.76% YoY) and the FY2025 annual result came in at $1.2 million, down 74.89% from the prior year.
• Other Non-Current Liabilities fell to $1.0 million in Q1 2026 per NEUP's latest filing, from $2.7 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $8.1 million in Q3 2025 and bottomed at $3389.0 in Q4 2024.
• The 5-year median for Other Non-Current Liabilities is $1.1 million (2025), against an average of $2.0 million.
• Peak annual rise in Other Non-Current Liabilities reached 235344.22% in 2025, while the deepest fall reached 74.89% in 2025.
• Tracing NEUP's Other Non-Current Liabilities over 5 years: stood at $7492.2 in 2022, then soared by 99.81% to $14969.9 in 2023, then plunged by 77.36% to $3389.0 in 2024, then surged by 79946.74% to $2.7 million in 2025, then sank by 62.26% to $1.0 million in 2026.
• Per Business Quant, the three latest NEUP Other Non-Current Liabilities figures stand at $1.0 million (Q1 2026), $2.7 million (Q4 2025), and $8.1 million (Q3 2025).

Peer Comparison